Sildenafil Teva

Country: European Union

Language: Slovenian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

sildenafil

Available from:

Teva B.V. 

ATC code:

G04BE03

INN (International Name):

sildenafil

Therapeutic group:

Zdravila, ki se uporabljajo pri erektilni disfunkciji

Therapeutic area:

Erektilna disfunkcija

Therapeutic indications:

Zdravljenje moških z erektilno disfunkcijo, ki ni sposobna doseči ali vzdrževati erekcije penisa, ki zadošča za zadovoljivo spolno delovanje. Da bi Sildenafil Teva, da bo učinkovito, spolne stimulacije je potrebno.

Product summary:

Revision: 17

Authorization status:

Pooblaščeni

Authorization date:

2009-11-30

Patient Information leaflet

                                21
10.
POSEBNI VARNOSTNI UKREPI ZA ODSTRANJEVANJE NEUPORABLJENIH
ZDRAVIL ALI IZ NJIH NASTALIH ODPADNIH SNOVI, KADAR SO POTREBNI
11.
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
Teva B.V.
Swensweg 5
2031GA Haarlem
Nizozemska
12.
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET
EU/1/09/584/002
EU/1/09/584/003
EU/1/09/584/004
EU/1/09/584/005
EU/1/09/584/006
13.
ŠTEVILKA SERIJE
_ _
Lot
14.
NAČIN IZDAJANJA ZDRAVILA
Predpisovanje in izdaja zdravila je le na recept.
15.
NAVODILA ZA UPORABO
16.
PODATKI V BRAILLOVI PISAVI
Sildenafil Teva 25 mg
17.
EDINSTVENA OZNAKA – DVODIMENZIONALNA ČRTNA KODA_ _
Vsebuje dvodimenzionalno črtno kodo z edinstveno oznako.
18.
EDINSTVENA OZNAKA – V BERLJIVI OBLIKI_ _
PC
SN
NN
22
PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA PRETISNEM OMOTU ALI
DVOJNEM TRAKU
PRETISNI OMOT – SILDENAFIL TEVA 25 MG FILMSKO OBLOŽENE TABLETE
1.
IME ZDRAVILA
Sildenafil Teva 25 mg filmsko obložene tablete
sildenafil
2.
IME IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
Teva B.V.
3.
DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA
EXP
4.
ŠTEVILKA SERIJE
Lot
5.
DRUGI PODATKI
23
PODATKI NA ZUNANJI OVOJNINI
ZUNANJA ŠKATLA – SILDENAFIL TEVA 50
MG FILMSKO OBLOŽENE TABLETE
1.
IME ZDRAVILA
Sildenafil Teva 50 mg filmsko obložene tablete
sildenafil
2.
NAVEDBA ENE ALI VEČ ZDRAVILNIH UČINKOVIN
Ena tableta vsebuje sildenafilijev citrat, ki ustreza 50 mg
sildenafila.
3.
SEZNAM POMOŽNIH SNOVI
4.
FARMACEVTSKA OBLIKA IN VSEBINA
2 filmsko obloženi tableti
4 filmsko obložene tablete
8 filmsko obloženih tablet
10 x 1 filmsko obložena tableta
12 filmsko obloženih tablet
24 filmsko obloženih tablet
5.
POSTOPEK IN POT(I) UPORABE
_ _
Pred uporabo preberite priloženo navodilo!
peroralna uporaba
6.
POSEBNO OPOZORILO O SHRANJEVANJU ZDRAVILA ZUNAJ DOSEGA IN
POGLEDA OTROK
Zdravilo shranjujte nedosegljivo otrokom!
7.
DRUGA POSEBNA OPOZORILA, ČE SO POTREBNA
8.
DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA
EXP
9.
POSEBNA NAVODILA ZA SHRANJEVANJE
Shranjujte v originalni ovojnini za zagotovitev zaščite pred vlago.
24
10.
POSEBNI VARNO
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
PRILOGA I
POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA
2
1.
IME ZDRAVILA
Sildenafil Teva 25 mg filmsko obložene tablete
Sildenafil Teva 50 mg filmsko obložene tablete
Sildenafil Teva 100 mg filmsko obložene tablete
2.
KAKOVOSTNA IN KOLIČINSKA SESTAVA
Sildenafil Teva 25 mg filmsko obložene tablete
Ena tableta vsebuje sildenafilijev citrat, ki ustreza 25 mg
sildenafila.
Sildenafil Teva 50 mg filmsko obložene tablete
Ena tableta vsebuje sildenafilijev citrat, ki ustreza 50 mg
sildenafila.
Sildenafil Teva 100 mg filmsko obložene tablete
Ena tableta vsebuje sildenafilijev citrat, ki ustreza 100 mg
sildenafila.
Za celoten seznam pomožnih snovi glejte poglavje 6.1.
3. FARMACEVTSKA OBLIKA
filmsko obložena tableta
Sildenafil Teva 25 mg filmsko obložene tablete
Bele, filmsko obložene tablete ovalne oblike, z vtisnjeno oznako ‘S
25’ na eni strani in brez oznak na
drugi strani.
Sildenafil Teva 50 mg filmsko obložene tablete
Bele, filmsko obložene tablete ovalne oblike, z vtisnjeno oznako ‘S
50’ na eni strani in brez oznak na
drugi strani.
Sildenafil Teva 100 mg filmsko obložene tablete
Bele, filmsko obložene tablete ovalne oblike, z vtisnjeno oznako ‘S
100’ na eni strani in brez oznak na
drugi strani.
4.
KLINIČNI PODATKI
4.1
TERAPEVTSKE INDIKACIJE
Zdravilo Sildenafil Teva je indicirano pri odraslih moških z
erektilno disfunkcijo, tj. nezmožnostjo
doseči ali ohraniti erekcijo penisa, ki bi zadoščala za zadovoljivo
spolno aktivnost.
Da bi bilo zdravilo Sildenafil Teva učinkovito, je potrebna spolna
stimulacija.
4.2
ODMERJANJE IN NAČIN UPORABE
Odmerjanje
_ _
_Uporaba pri odraslih _
Priporočeni odmerek je 50 mg, uporabljen kot je potrebno, približno
eno uro pred spolno dejavnostjo.
Glede na učinkovitost in prenašanje je odmerek mogoče zvečati na
100 mg ali zmanjšati na 25 mg.
Največji priporočeni odmerek je 100 mg. Največja priporočena
pogostnost odmerjanja je enkrat na
dan. Če se zdravilo Sildenafil Teva zaužije s hrano, lahko začne
delovati pozneje, kot če je zaužito na
prazen že
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 04-07-2022
Summary of Product characteristics Summary of Product characteristics Bulgarian 04-07-2022
Public Assessment Report Public Assessment Report Bulgarian 30-11-2012
Patient Information leaflet Patient Information leaflet Spanish 04-07-2022
Public Assessment Report Public Assessment Report Spanish 30-11-2012
Patient Information leaflet Patient Information leaflet Czech 04-07-2022
Public Assessment Report Public Assessment Report Czech 30-11-2012
Patient Information leaflet Patient Information leaflet Danish 04-07-2022
Public Assessment Report Public Assessment Report Danish 30-11-2012
Patient Information leaflet Patient Information leaflet German 04-07-2022
Public Assessment Report Public Assessment Report German 30-11-2012
Patient Information leaflet Patient Information leaflet Estonian 04-07-2022
Public Assessment Report Public Assessment Report Estonian 30-11-2012
Patient Information leaflet Patient Information leaflet Greek 04-07-2022
Public Assessment Report Public Assessment Report Greek 30-11-2012
Patient Information leaflet Patient Information leaflet English 04-07-2022
Public Assessment Report Public Assessment Report English 30-11-2012
Patient Information leaflet Patient Information leaflet French 04-07-2022
Public Assessment Report Public Assessment Report French 30-11-2012
Patient Information leaflet Patient Information leaflet Italian 04-07-2022
Public Assessment Report Public Assessment Report Italian 30-11-2012
Patient Information leaflet Patient Information leaflet Latvian 04-07-2022
Public Assessment Report Public Assessment Report Latvian 30-11-2012
Patient Information leaflet Patient Information leaflet Lithuanian 04-07-2022
Summary of Product characteristics Summary of Product characteristics Lithuanian 04-07-2022
Public Assessment Report Public Assessment Report Lithuanian 30-11-2012
Patient Information leaflet Patient Information leaflet Hungarian 04-07-2022
Summary of Product characteristics Summary of Product characteristics Hungarian 04-07-2022
Public Assessment Report Public Assessment Report Hungarian 30-11-2012
Patient Information leaflet Patient Information leaflet Maltese 04-07-2022
Public Assessment Report Public Assessment Report Maltese 30-11-2012
Patient Information leaflet Patient Information leaflet Dutch 04-07-2022
Public Assessment Report Public Assessment Report Dutch 30-11-2012
Patient Information leaflet Patient Information leaflet Polish 04-07-2022
Public Assessment Report Public Assessment Report Polish 30-11-2012
Patient Information leaflet Patient Information leaflet Portuguese 04-07-2022
Summary of Product characteristics Summary of Product characteristics Portuguese 04-07-2022
Public Assessment Report Public Assessment Report Portuguese 30-11-2012
Patient Information leaflet Patient Information leaflet Romanian 04-07-2022
Public Assessment Report Public Assessment Report Romanian 30-11-2012
Patient Information leaflet Patient Information leaflet Slovak 04-07-2022
Public Assessment Report Public Assessment Report Slovak 30-11-2012
Patient Information leaflet Patient Information leaflet Finnish 04-07-2022
Public Assessment Report Public Assessment Report Finnish 30-11-2012
Patient Information leaflet Patient Information leaflet Swedish 04-07-2022
Public Assessment Report Public Assessment Report Swedish 30-11-2012
Patient Information leaflet Patient Information leaflet Norwegian 04-07-2022
Summary of Product characteristics Summary of Product characteristics Norwegian 04-07-2022
Patient Information leaflet Patient Information leaflet Icelandic 04-07-2022
Summary of Product characteristics Summary of Product characteristics Icelandic 04-07-2022
Patient Information leaflet Patient Information leaflet Croatian 04-07-2022

Search alerts related to this product